Search

News An Introductory Word to the Section on Hereditary Angioedema —⁠ MUDr. Roman Hakl, Ph.D.

Hereditary angioedema (HAE) is a genetically conditioned disease, currently classified into HAE with C1 inhibitor deficiency (HAE-C1-INH), referred to as HAE-I and HAE-II, and HAE with normal level and function of C1 inhibitor (HAE nC1-INH), also referred to as HAE-III (1).

Source: Hereditary Angioedema 29. 7. 2020

News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics

The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.

Source: Heart Failure 2. 12. 2021

News How to Communicate and Receive an Oncological Diagnosis

Communicating the truth to a patient about their health condition does not have a very long tradition in the Czech Republic. The Czech healthcare system started emphasizing this aspect, i.e., honest and open communication between doctor and patient, several years after the Velvet Revolution.

Source: Ovarian and Breast Cancer 4. 6. 2020

News Tofacitinib in the Treatment of Ulcerative Colitis in Real-World Practice in the USA

A recently published study summarizes the characteristics of patients newly treated with tofacitinib for ulcerative colitis (UC), the impact of initiating tofacitinib on corticosteroid use, and adherence to this treatment in real-world practice based on a retrospective analysis of data from a large health database in the USA.

Source: Intestinal Inflammations 22. 6. 2023

News Tofacitinib Through the Eyes of Patients: Rapid Response After Treatment Initiation

How does tofacitinib fare in the treatment of ulcerative colitis in real clinical practice from the patients' perspective? This was addressed in a recent study published in the journal Inflammatory Bowel Diseases.

Source: Intestinal Inflammations 5. 7. 2023

News New scoring system for predicting long-term survival of AML patients over 70 years and suitable for intensive chemotherapy

Based on the analysis of data from 3 large European registries (DATAML, SAL, and PETHEMA), a prognostic score for 5-year survival was created and validated for patients with acute myeloid leukemia (AML) who were given intensive chemotherapy. The ESS70+ score, determined based on parameters known at the time of diagnosis, is easily usable in routine practice for estimating overall survival of older AML patients and facilitates decisions about intensive chemotherapy.

Source: Acute Myeloid Leukemia 10. 5. 2024

News Effect of Initiation of Warfarin Therapy on the Risk of Ischemic Stroke

Anticoagulant therapy is essential in patients with atrial fibrillation for the prevention of thromboembolic events. Warfarin is a highly effective anticoagulant, but the introduction of new oral anticoagulants (NOACs) has offered certain advantages over it. Shortly after starting warfarin therapy, patients have repeatedly been shown to have a paradoxically increased risk of developing ischemic stroke. The aim of the study presented below was to determine whether this increase in risk is associated with the initiation of anticoagulant therapy.

Source: Anticoagulant Treatment 17. 7. 2020

News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism

The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.

Source: Thyroid Disorders 14. 9. 2022

News Effect of Cataract Surgery on Melatonin Secretion in Adults Aged 60 and Over

A study by ophthalmologists and epidemiologists from Nara University in Japan, recently published in JAMA Ophthalmology, examined the relationship between cataract surgery, the use of clear and yellow intraocular lenses, and the level of melatonin secretion.

Source: Glaucoma 8. 6. 2020

News Somapacitan administered once weekly in the treatment of children with growth hormone deficiency –⁠ current understanding

Somapacitan is a long-acting derivative of recombinant human growth hormone approved for the treatment of children and adults with growth hormone (GH) deficiency. Dr. Reiko Horikawa from Japan's National Center for Child Health and Development in Tokyo, during the 24th Pediatric Endocrinology Days held in Brno in January 2024, showed that it is a promising therapeutic option for pediatric patients from 3 years of age, thanks to its efficacy, safety, and potential to improve therapy adherence. However, careful long-term monitoring of the safety of long-acting growth hormone (LAGH) products is still necessary.

Source: Growth Disorders 12. 6. 2024

News With MD Eva Drbohlavová on Innovations in the Treatment of von Willebrand Disease and Improving Patients' Quality of Life

Von Willebrand Disease (vWD), as the most common congenital bleeding disorder, remains underdiagnosed. However, thanks to new insights and advances in genetic testing, both diagnosis and long-term prophylaxis of the disease are gradually improving, leading to a significant reduction in bleeding and better quality of life for patients. We discuss this in more detail with MD Eva Drbohlavová from the Department of Clinical Hematology at the Regional Hospital Liberec.

Source: Von Willebrand Disease 17. 7. 2024

News Treatment of Comorbidities of Atopic Dermatitis in One Go and Where to Refer Candidates for Biologic Therapy

Patients suffering from atopic dermatitis (AD) along with allergic comorbidities typically require a fairly complex pharmacotherapy to manage their difficulties. However, their everyday lives can be significantly simplified with biological therapy.

Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 19. 10. 2020

News Results of a 10-year follow-up on the safety and efficacy of etanercept treatment in patients with juvenile idiopathic arthritis

Juvenile idiopathic arthritis (JIA) is defined as persistent arthritis of unknown etiology lasting > 6 weeks with the first onset before the age of 16. In the treatment of JIA, non-steroidal anti-inflammatory drugs (NSAIDs), intra-articular corticosteroid injections, and conventional disease-modifying antirheumatic drugs (DMARDs) are typically utilized. In case of inadequate response, targeted biological therapy can also be used. An effective and well-tolerated drug for the treatment of polyarticular JIA is the tumor necrosis factor alpha (TNF-α) inhibitor etanercept. The results of its use in various forms of JIA were examined in the CLIPPER and CLIPPER2 studies.

Source: Arthritis 10. 7. 2023

News Are there mutual interactions between candesartan and amlodipine in the combination therapy of hypertension?

Monotherapy is often insufficient in the treatment of hypertension; however, combining antihypertensives with different mechanisms of action can be complicated by their mutual interactions. Therefore, a study by South Korean authors examined the pharmacokinetic interactions between candesartan and amlodipine, substances that are commonly used together in combined treatment.

Source: Sartans in the Treatment of Hypertension 14. 6. 2021

News Importance of Home Parenteral Therapy: ESPEN Recommendations from 2020

Home parenteral therapy currently plays a crucial role in the treatment and prevention of malnutrition in specific patient groups. The European Society for Clinical Nutrition and Metabolism (ESPEN) published updated guidelines for home parenteral therapy in 2020, based on current evidence and expert recommendations.

Source: Parenteral Nutrition 7. 6. 2021